The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Informa
Skip to Page Content

Full Deal Summary

Siga Technologies Inc. sold its material threat medical countermeasure priority review voucher (PRV) to Eli Lilly & Co. for $80mm. Lilly did not disclose its plans for the voucher. The PRV is the first for a medical countermeasure issued by the FDA; it has previously issued vouchers for rare pediatric diseases and tropical diseases. Siga obtained the PRV in July following approval of its (TPOXX} (tecovirimat) smallpox drug.


+ Show All | – Hide All

Financials


Click a figure for comparable deals.

Overview
Potential Deal Value $80.00mm
Transactions 1 of 1 (11/2018)
Cash $80.00mm
Total Line Value $80.00mm
Gross Proceeds $80.00mm

Deal Information


Click a keyword for comparable deals.

Deal Industry Biotechnology
Pharmaceuticals
Deal Status Final
Deal Type Financing
Other

Company Information


Click a keyword for comparable companies.

Eli Lilly & Co. www.lilly.com | Ticker: LLY
View Company Profile | View Company Deals
Company Location Worldwide
North America
USA
IN
Industry Pharmaceuticals
Description Big Pharma
Ownership Public
Therapeutic Area(s) of Focus Cancer
Cardiovascular
Infectious & Viral Diseases
Metabolic Disorders
Neurology, Nervous System

Siga Technologies Inc. www.siga.com | Ticker: SIGA
View Company Profile | View Company Deals
Company Location Worldwide
North America
USA
NY
Industry Biotechnology
Drug Discovery Tools
Genomics-Proteomics
Pharmaceuticals
Vaccines
Ownership Public
Therapeutic Area(s) of Focus Infectious & Viral Diseases
Alias(es) Siga Pharmaceuticals Inc.